

典型的パターンとともに40%の一致率に留まっており、典型的パターンにおいては、大うつ病性障害の患者が47%と約半数を占め、典型的パターンの方が占める割合が多くなっている。さらに、追跡調査可能な60名中8名が軽躁エピソードを示し、双極性障害へ診断変更され、37名が気分安定薬を併用している事実からも、大うつ病性障害の患者がNIRSで双極性障害パターンを示した場合は、真の診断は双極性障害となるか、気分安定薬が有効な大うつ病性障害となるか、いずれかの可能性がある。

躁状態や軽躁状態が顕在化していない潜在性の躁うつ病が大うつ病性障害と診断されていたり、患者が軽躁状態を正常と考え申告していない例もあると考えられ、他のパターンと比べて明らかに一致率が低いのは、真の診断に迫っている可能性が示唆される。今後追跡調査をすることで、真の診断との一致率が判明するものと考えられる。

E. 結論

今回の研究によって NIRS が大うつ病性障害、統合失調症パターンを示した場合は高い確率で診断補助として有用であり、大うつ病性障害の患者が双極性障害パターンを示した場合は診断変更を念頭において躁転に注意して経過を追うことが有効であると考えられた。

(参考文献)

- 1) 滝沢龍, 福田正人. 精神疾患の臨床検査としての光トポグラフィ検査 (NIRS) —先進医療「うつ症状の鑑別診断補助」—. MEDIX 2010; 53: 30-5.

F. 研究発表

1. 論文発表

- 1) Noda T, Yoshida S, Matsuda T, Okamoto N, Sakamoto K, Koseki S, Numachi Y, Matsushima E, Kunugi H, Higuchi T. Frontal and right temporal activations correlate negatively with depression severity during verbal fluency task: A multi-channel near-infrared spectroscopy study. Journal of Psychiatric Research, 46: 905-912, 2012.

- 2) 野田隆政, 中込和幸. シンポジウム 精神疾患の診断ツールとしての光トポグラフィ, 認知神経科学, 14: 35-41, 2012.
- 3) 野田隆政. 光トポグラフィによるうつ病診断, 医学のあゆみ 244: 425-431, 2013.
- 4) 野田隆政, 安藤久美子, 清水悠. 精神症状への対応, 多発性硬化症 (MS) 診療のすべて, 山村隆編, 診断と治療社, 東京, 2012.
- 5) 野田隆政, 松田太郎, 蟹江絢子, 安藤久美子. 頭蓋内疾患によるせん妄, 病棟・ICUで出会うせん妄の診かた, 八田耕太郎, 岸泰宏編, 中外医学社, 第2章 1節 pp.20-32, 東京, 2012.
- 6) 野田隆政. 精神症状, やさしいパーキンソン病の自己管理 (改訂版), 村田美穂編, 医薬ジャーナル社, 第1章 5節 31-36, 大阪, 2012.

2. 学会発表

- 1) 野田隆政, 松田太郎, 功刀浩, 吉田寿美子, 中込和幸, 樋口輝彦. 気分障害における認知機能障害の臨床的意義, 第9回日本うつ病学会総会, 東京, 7.28, 2012.
- 2) 野田隆政, 中込和幸. NIRSの基礎と限界—症例を中心に光トポグラフィ外来—, 第34回日本生物学的精神医学会年会シンポジウム, 神戸, 9.28, 2012.
- 3) 野田隆政, 花川隆, 守口善也, 中込和幸, NIRSを用いた精神疾患研究 NIRS-fMRI 同時計測, 第42回日本臨床神経生理学会学術大会シンポジウム, 東京, 11.8, 2012.

G. 知的財産権の出願・登録状況 (予定を含む)

1. 特許取得

該当なし。

2. 実用新案登録

該当なし。

3. その他

該当なし。

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
M Ikeda, B Aleksic, K Yamada, Y Iwayama-Shigeno, K Matsuo, S Numata, Y Watanabe, T Ohnuma, T Kaneko, Y Fukuo, T Okochi, T Toyota, E Hattori, S Shimodera, M Itakura, A Nunokawa, N Shibata, H Tanaka, H Yoneda, H Arai, T Someya, T Ohmori, T Yoshikawa, N Ozaki, and N Iwata	Genetic evidence for association between NOTCH4 and schizophrenia supported by a GWAS follow-up study in a Japanese population	Molecular Psychiatry	in press		2012
S Matsunaga, M Ikeda, T Kishi, Y Fukuo, B Aleksic, R Yoshimura, T Okochi, Y Yamanouchi, Y Kinoshita, K Kawashima, W Umene-Nakano, T Inada, H Kunugi, T Kato, T Yoshikawa, H Ujike, J Nakamura, N Ozaki, T Kitajima, and N Iwata	An evaluation of polymorphisms in casein kinase 1 delta and epsilon genes in major psychiatric disorders	Neuroscience letters	529(1)	66-9	2012
Kushima I, Nakamura Y, Aleksic B, Ikeda M, Ito Y, Shiino T, Okochi T, Fukuo Y, Ujike H, Suzuki M, Inada T, Hashimoto R, Takeda M, Kaibuchi K, Iwata N, Ozaki N	Resequencing and Association Analysis of the KALRN and EPHB1 Genes And Their Contribution to Schizophrenia Susceptibility.	Schizophr Bull	38 (3)	552-60	2012
Torii Y, Iritani S, Sekiguchi H, Habuchi C, Hagikura M, Arai T, Ikeda K, Akiyama H, Ozaki N	Effects of aging on the morphologies of Heschl's gyrus and the superior temporal gyrus in schizophrenia: A postmortem study.	Schizophr Res	134 (2-3)	137-42	2012

Uno Y, Uchiyama T, Kurosawa M, Aleksic B, Ozaki N	The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: The first case-control study in Asia.	Vaccine	30 (28)	4292-8	2012
Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Yamamori H, Umeda-Yano S, Okada T, Kamino K, Morihara T, Iwase M, Kazui H, Numata S, Ikeda M, Ohmura T, Iwata N, Ueno S, Ozaki N, Ohmori T, Arai H, Takeda M	Functional genetic variation at the NRG1 gene and schizophrenia: evidence from a gene-based case-control study and gene expression analysis.	American Journal of Medical Genetics Part B: Neuropsychiatric Genetics	159B(4)	405-13	2012
Ohi K, Hashimoto R, Nakazawa T, Okada T, Yasuda Y, Yamamori H, Fukumoto M, Umeda-Yano S, Iwase M, Kazui H, Yamamoto T, Kano M, Takeda M.	The p250GAP Gene is Associated with Risk for Schizophrenia and Schizotypal Personality Traits.	PLoS One	7(4)	e35696	2012
Noda T, Yoshida S, Matsuda T, Okamoto N, Sakamoto K, Koseki S, Numachi Y, Matsushima E, Kunugi H, Higuchi T	Frontal and right temporal activations correlate negatively with depression severity during verbal fluency task: A multi-channel near-infrared spectroscopy study	Journal of Psychiatric Research	46	905-912	2012
野田隆政, 中込和幸	シンポジウム 精神疾患の診断ツールとしての光トポグラフィ	認知神経科学	14	35-41	2012
野田隆政	光トポグラフィによるうつ病診断	医学のあゆみ	244	425-431	2013
野田隆政, 安藤 久美子, 平林直次, 大森まゆ, 黒木規臣, 岡田幸之	医療観察法における ECT のインフォームド・コンセント	精神神経学雑誌	114 第10 7回学術総 会特別号	SS385-SS390	2013

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
野田隆政, 安藤久美子, 清水悠	精神症状への対応	山村隆	多発性硬化症 (MS) 診療 のすべて	診断と治療 社	東京	2012	91-98
野田隆政, 松田太郎, 蟹江絢子, 安藤久美子.	頭蓋内疾患による せん妄	八田耕太 郎、岸泰宏	病棟・ICUで 出会うせん妄 の診かた	中外医学社	東京	2012	20-32
野田隆政	精神症状	村田美穂	やさしいパー キンソン病の 自己管理 (改 訂版)	医薬ジャー ナル社	大阪	2012	31-36

LETTER TO THE EDITOR

Genetic evidence for association between *NOTCH4* and schizophrenia supported by a GWAS follow-up study in a Japanese population

Molecular Psychiatry advance online publication, 29 May 2012;
 doi:10.1038/mp.2012.74

Using stringent criteria, we followed-up a genome-wide association study (GWAS) finding¹ to examine the involvement of the developmental regulatory gene *NOTCH4* in schizophrenia. This is the first study in a Japanese population that satisfies genome-wide significance between a particular single-nucleotide polymorphism (SNP) and schizophrenia.

The past 5 years have seen significant genetic discoveries made through GWASs. Although in schizophrenia the effect sizes have been relatively small (odds ratio (OR) of <1.2), these studies collectively provide strong evidence for association of a number of susceptibility genes. The major loci identified for schizophrenia risk are located in the major histocompatibility complex region in 6p21.3–p22.1. The Psychiatric GWAS Consortium, a sample consisting mainly of Caucasian subjects, reported 136 SNPs with genome-wide significance (5×10^{-8}), and among them 129 SNPs were located from 25 to 33 Mb at chromosome 6.² In addition, a recent Asian GWAS from a Chinese population showed a stringent level of significance at *ZKSCAN4* (chr6: 28.32 Mb),³ even though another larger Chinese population GWAS⁴ and our prior Japanese population-based GWAS (total sample size: 1108)¹ did not detect any genome-wide significance in this region. In our previous study,¹ however, only one signal within these loci maximized at a SNP (rs2071287: chr6: 32 170 433 bp on hg19) in *NOTCH4* (chr6: 32.16 to 32.19 Mb). To provide a more complete analysis, in the current study, we expanded the sample size to verify whether this SNP (rs2071287: C>T) in *NOTCH4* shows strong support for genetic association.

Six case–control data sets from Japanese population, including our screening GWAS (JPN_GWAS), replication set (Rep_JPN) and the sample of Tochigi *et al.*,¹ were evaluated. The other three new data sets consist of REP1, REP2 and REP3, the sample sets being divided by the collection regions in Japan: REP1 (Mid-east Japan: case = 3173, control = 3540), REP2 (Mid-west Japan: case = 672, control = 5321), and REP3 (South island of Japan (Shikoku):

case = 569, control = 1622) (Supplementary Method). The TaqMan assay (Applied Biosystems, Foster City, CA, USA) was used to determine the genotypic distribution of rs2071287. A meta-analysis was performed with a fixed model by 'rmeta', an R package, as we did not apply a principal component analysis, which is the most common approach to adjust the population structure. Instead, we conducted a stratified analysis according to the sample collection site in order to rule out possible population stratification. A test for heterogeneity did not show significant deviation for combined replication data sets (REP1–REP3, $\chi^2 = 0.63$, $df = 2$, $P = 0.73$) and all data sets, including samples from our prior study ($\chi^2 = 4.2$, $df = 5$, $P = 0.52$).

Previously, we reported an association based upon three data sets with P_{meta} at 5.1×10^{-5} and OR of 0.83 (reference: T allele: minor allele, 95% confidence intervals: CIs: 0.77–0.91: 'Summary1' in Figure 1).¹ In the current study, in two out of three replication sets, we detected statistical evidence ($P < 0.05$, two-tailed) for a consistent association that was similar in magnitude and direction (T allele in control is more frequent than in case: Figure 1). Further meta-analysis of the combined samples for the new data sets (REP1–REP3: case = 4414, control = 10 483) suggests strong support for the association of this SNP ($P = 7.9 \times 10^{-5}$: OR = 0.89, 95% CI = 0.84–0.94, 'Summary2' in Figure 1). Finally, genome-wide significance was detected in the meta-analysis combining all of the data sets (6668 case and 12 791 controls) in the Japanese population ($P = 3.4 \times 10^{-8}$: OR = 0.87, 95% CI = 0.83–0.92, 'ALL combined' in Figure 1).

Our results provide stringent support for previous genetic findings reporting the association of an intronic SNP (rs3131296, chr6: 32 172 993 bp on hg19) in *NOTCH4* in a European cohort.⁵ However, the pattern of linkage disequilibrium (LD) between the current (rs2071287) and previous (rs3131296) SNPs, in addition to the minor allele frequencies (MAFs) of these SNPs vary across populations (Supplementary Figures 1 and 2): (1) a greater level of LD is observed in the Caucasian (HapMap CEU, release28, $D' = 1$, $r^2 = 0.13$) compared with the Japanese population (HapMap JPT, release28, $D' = 0.49$, $r^2 = 0$); and (2) rs3131296, the SGENE-plus study⁵ reported significant association, shows substantially higher




Figure 1. Association of rs2071287 with schizophrenia.

MAF in Caucasian (8.5% in HapMap CEU, 13% in SGENE-plus) than in Japanese (1.9% in HapMap JPT). Considering that the major histocompatibility complex region consists of large blocks with a very high LD,⁶ it would be difficult to ascribe the difference to particular SNP(s). Nevertheless, given the evidence for the association of *NOTCH4* with schizophrenia based upon current and previous genetic and biological support,⁷ we suggest that *NOTCH4* remains one of the strongest candidate susceptibility genes for schizophrenia, and we propose this SNP is a key to the identification of causal variant(s).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by research grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Ministry of Health, Labor and Welfare of Japan; Academic Frontier Project for Private Universities, Comparative Cognitive Science Institutes; Core Research for Evolutional Science and Technology; Uehara Memorial Foundation; SENSHIN Medical Research Foundation; Takeda Science Foundation; Novaltis Foundation, Japan; Strategic Research Program for Brain Sciences of the MEXT of Japan.

M Ikeda^{1,2}, B Alekscic^{2,3}, K Yamada⁴, Y Iwayama-Shigeno⁴, K Matsuo⁵, S Numata⁶, Y Watanabe⁷, T Ohnuma⁸, T Kaneko⁹, Y Fukuo^{1,2}, T Okochi^{1,2}, T Toyota⁴, E Hattori⁴, S Shimodera¹⁰, M Itakura¹¹, A Nunokawa⁷, N Shibata⁸, H Tanaka⁵, H Yoneda⁹, H Arai⁸, T Someya⁷, T Ohmori⁶, T Yoshikawa⁴, N Ozaki^{2,3} and N Iwata^{1,2}

¹Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan;

²Japan Science and Technology Agency, The Core Research for Evolutional Science and Technology, Kawaguchi, Japan;

³Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan;

⁴Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan;

⁵Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan;

⁶Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan;

⁷Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan;

⁸Department of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan;

⁹Department of Neuropsychiatry, Osaka Medical College, Osaka, Japan;

¹⁰Department of Neuropsychiatry, Kochi Medical School, Kochi, Japan and


¹¹Division of Genetic Information, Institute for Genome Research, The University of Tokushima Graduate School of Medicine, Tokushima, Japan

E-mail: nakao@fujita-hu.ac.jp

REFERENCES

- Ikeda M, Alekscic B, Kinoshita Y, Okochi T, Kawashima K, Kushima I et al. *Biol Psychiatry* 2011; **69**: 472–478.
- Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA et al. *Nat Genet* 2011; **43**: 969–976.
- Yue WH, Wang HF, Sun LD, Tang FL, Liu ZH, Zhang HX et al. *Nat Genet* 2011; **43**: 1228–1231.
- Shi Y, Li Z, Xu Q, Wang T, Li T, Shen J et al. *Nat Genet* 2011; **43**: 1224–1227.
- Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D et al. *Nature* 2009; **460**: 744–747.
- Jeffreys AJ, Kauppi L, Neumann R. *Nat Genet* 2001; **29**: 217–222.
- Imayoshi I, Kageyama R. *Mol Neurobiol* 2011; **44**: 7–12.

Supplementary Information accompanies the paper on the Molecular Psychiatry website (<http://www.nature.com/mp>)



An evaluation of polymorphisms in casein kinase 1 delta and epsilon genes in major psychiatric disorders

Shinji Matsunaga^{a,b}, Masashi Ikeda^{a,b,*}, Taro Kishi^{a,c}, Yasuhisa Fukuo^{a,b}, Branko Aleksic^{b,d}, Reiji Yoshimura^e, Tomo Okochi^{a,b}, Yoshio Yamanouchi^a, Yoko Kinoshita^a, Kunihiro Kawashima^a, Wakako Umene-Nakano^e, Toshiya Inada^f, Hiroshi Kunugi^g, Tadafumi Kato^h, Takeo Yoshikawaⁱ, Hiroshi Ujike^j, Jun Nakamura^e, Norio Ozaki^{b,d}, Tsuyoshi Kitajima^a, Nakao Iwata^{a,b}

^a Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

^b Japan Science and Technology Agency, the Core Research for Evolutional Science and Technology, Kawaguchi, Japan

^c Department of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY, USA

^d Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan

^e Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

^f Seiwa Hospital, Institute of Neuropsychiatry, Tokyo, Japan

^g National Center of Neurology and Psychiatry, Mental Disorder Research, National Institute of Neuroscience, Tokyo, Japan

^h Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Brain Science Institute, Saitama, Japan

ⁱ Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan

^j Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan

HIGHLIGHTS

- ▶ We report the candidate gene analysis of *CSNK1D*/*CSNK1E* with psychiatric disorders.
- ▶ Two-stage analysis was carried out using large sample size.
- ▶ No association was detected in bipolar disorder, schizophrenia and depression.
- ▶ These genes may not play a major role in the risk of major psychiatric disorders.

ARTICLE INFO

Article history:

Received 9 July 2012

Received in revised form 31 July 2012

Accepted 8 August 2012

Keywords:

Schizophrenia

Bipolar disorder

Major depressive disorder

Single nucleotide polymorphism

ABSTRACT

Disturbances of the circadian rhythm are involved in the pathophysiology of bipolar disorder (BD), schizophrenia (SCZ) and major depressive disorder (MDD). Specifically, because clock gene dysfunction is good candidate for enhancing the susceptibility to these psychiatric disorders, we selected two circadian rhythm-related genes (*CSNK1D* and *CSNK1E*) and investigated genetic associations of the genes with these three disorders.

None of the SNPs showed a significant association with MDD, but a SNP (rs2075984) in *CSNK1E* and SNP (rs6502097) in *CSNK1D* were associated with SCZ ($P=0.0091$, uncorrected) and BD ($P=0.030$, uncorrected), respectively. To confirm these findings, we analyzed an independent dataset (maximum $N=3815$) but found a lack of association ($P=0.63$ for rs2075984 and $P=0.61$ for rs6502097). The final meta-analysis showed no association between these SNPs with SCZ ($P=0.21$) and BD ($P=0.53$). These results do not support that genetic variation in *CSNK1D* and *CSNK1E* is a susceptibility factor for major psychiatric disorders in the Japanese population.

© 2012 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

As patients with psychiatric disorders often show various rhythm disturbances, including sleep–wake disruption, abnormalities in the circadian system have been hypothesized to be involved in the pathophysiology of these disorders [4,10]. Typically, in mood disorders such as bipolar disorder (BD) and major depressive disorder (MDD), many patients demonstrate sleep disturbances, social rhythm maladaptation and appetite and hormonal rhythm changes

Abbreviations: MDD, major depressive disorder; BD, bipolar disorder; SCZ, schizophrenia; *CSNK1D*, casein kinase 1 delta; *CSNK1E*, casein kinase 1 epsilon; SNP, single nucleotide polymorphism; OR, odds ratio.

* Corresponding author at: Department of Psychiatry, School of Medicine, Fujita Health University, Toyoake, Aichi 470-1192, Japan. Tel.: +81 562 93 9250; fax: +81 562 93 1831.

E-mail address: ikedema@fujita-hu.ac.jp (M. Ikeda).

[5]. Therefore, chronobiological interventions (e.g., sleep deprivation and light therapy) have been shown to be promising treatment options for mood disorders [19]. Potent mood stabilizers, such as lithium and valproic acid, are also known to modulate circadian rhythms via the circadian rhythm-related genes [2,24]. For schizophrenia (SCZ), a recent study reported disruptions in sleep and circadian rhythm disturbances in patients with SCZ, despite a lack of changes in melatonin production [22]. The anatomical center of the circadian rhythm is in the hypothalamic suprachiasmatic nucleus, which is regulated by the transcription of genes related to the circadian rhythm pathway (GO: 7623) [21], i.e., the so-called clock genes.

Casein kinase 1 delta (*CSNK1D*) and epsilon (*CSNK1E*) are members of the clock gene family and act as serine/threonine protein kinases that phosphorylate period (*PER*), a core member of the circadian clock gene group. Several lines of evidence suggest that homologs of human *CSNK1D* and *CSNK1E* have essential roles in circadian rhythm generation in mammals [11]. In a human study, for example, a point mutation in *CSNK1D* has causality in familial advanced sleep phase syndrome [23]. Another study also reported that *CSNK1E* is associated with circadian rhythm sleep disorders [17]. These findings indicate that the two genes have potential to affect human phenotypes relating to circadian rhythm regulation. In addition, Casein kinase 1 indirectly modulates the dopaminergic neurotransmitter system, which is well known to be involved in the pathophysiology of SCZ and mood disorders. First, casein kinase 1 interacts with Darpp-32 (Dopamine-And-cAMP-Regulated-Phosphoprotein-32 kDa) [3], which has a key role in dopaminergic neurotransmission. Second, recent animal studies suggest that casein kinase 1 is associated with altered locomotor activities by regulating dopaminergic signaling [1,25]. Finally, a human genetic study reported that a single nucleotide polymorphism (SNP: rs135745) in *CSNK1E* was associated with the subjective response to *D*-amphetamine [20].

Based on these data collectively, we hypothesized that *CSNK1D* and *CSNK1E* may have a possible role in a shared pathophysiology of a broad range of psychiatric disorders. More recently, a genetic case–control association analysis indicated that the same SNP (rs135745) in *CSNK1E* was significantly associated with SCZ-susceptibility in the Chinese population [7], although several reports did not detect the consistent evidence for the association between SNPs in these two genes and psychiatric disorders [8,9,15,16]; these indicate that another study with larger sample size and robust method is needed. In this study, we conducted a two-stage genetic association study in which significantly associated SNPs detected in the first-set screening sample were followed up in independent replication sample.

2. Materials and methods

2.1. Subjects

Two independent sample sets were used in this study. In the first-set screening analysis, we used 1004 patients with BD (492 males and 512 females; mean age \pm standard deviation; 50.0 ± 14.4 years, BDI=710, BDII=291, schizoaffective disorder=3), 808 patients with SCZ (443 males and 365 females; 46.1 ± 15.1 years), 452 patients with MDD (209 males and 243 females; 48.5 ± 16.1 years) and 1712 healthy controls (922 males and 790 females; 44.7 ± 15.2 years).

For rs2075984 and rs6502097, which showed a significant association with SCZ ($P=0.0091$) and BD ($P=0.030$), respectively, we used independent datasets consisting of 1380 patients with SCZ (718 males and 662 females; 49.0 ± 15.0 years), 324 patients with BD (163 males and 161 females; 47.6 ± 14.0 years, BDI=118,

BDII=206) and 1502 healthy controls (782 males and 720 females; 46.6 ± 15.2 years). Specifically for rs2075984, 933 unscreened controls from the public database of Japanese Single Nucleotide Polymorphisms (JSNP) were used to increase the sample size. A detailed description of the general characterization and psychiatric assessment of our subjects is available in the Supplementary methods section. Written informed consent was obtained from each subject. This study was approved by the ethics committees at Fujita Health University, University of Occupational and Environmental Health, and institutes participating in the Collaborative Study of Mood Disorder (COSMO).

2.2. SNP selection and quality control

Four tagging SNPs within *CSNK1D* and seven tagging SNPs within *CSNK1E* were selected based upon HapMap information (note: although rs6502097 is an intronic SNP in another gene [*SECTM1*], we included this SNP to cover the 5' region of *CSNK1D*). All of the SNPs were genotyped using a TaqMan assay (Supplementary text).

Quality control for genotyping was applied based upon the missing rate per person (excluded if more than 4 of 11 SNPs failed) and per SNP (included if less than 10%). A total of 128 subjects (7 BD, 40 MDD, 13 SCZ and 68 controls) were removed from the following association analysis. None of the SNPs were removed from the analysis.

2.3. Statistical analysis

Genotype deviation from the Hardy–Weinberg equilibrium and allelic associations were evaluated using the chi-square test. For the significant SNPs in the screening SCZ or BD datasets (rs2075984 and rs6502097) and rs135745 that was associated with SCZ in the Chinese population [7], we conducted a meta-analysis combining screening and replication datasets (rs2075984 and rs6502097) or results from our screening sample and Huang's data (rs135745) using a random-effect model because the I^2 heterogeneity index was relatively high ($I^2=67.4$ for rs2075984, 62.5 for rs6502097 and 72.5 for rs135745). All of the statistical procedures were calculated using PLINK ver1.07 [14].

The significance level for all statistical tests was 0.05. To correct for multiple testing, we used two-stage analysis, which provides conservative results if a significant association is detected in the screening sample.

3. Results

We observed a significant association between rs2075984 in *CSNK1E* with SCZ ($P=0.0091$, odds ratio (OR)=0.85) and a nominal association between rs6502097 in *CSNK1D* with BD ($P=0.030$, OR=1.19). To exclude the possibility of genotyping errors, we genotyped randomly selected samples from the first-set screening dataset using direct sequencing using ABI 3100 (case=83, control=94). We found 100% concordance between genotypes (data not shown), indicating that the observed statistical significance was not derived from mistakenly assigned genotype calls.

Rs135745, which was associated with SCZ in the Chinese population [7], did not show a significant association in our screening dataset ($P=0.12$). We next conducted a meta-analysis of this SNP in SCZ, combining our screening data and that from Huang et al. [7]. Although the direction of the effect size was same, we found non-significant trend for association ($P=0.095$, OR=1.26). In the MDD samples, none of the SNPs showed a significant association between the tagging SNPs in these genes.

In the following replication analysis using an independent case–control dataset (SCZ=1380, control=2435 for rs2075984 and BD=324, control=1502 for rs6502097), no association was

Table 1
Association analysis of SNPs in *CSNK1D* and *CSNK1E* with major psychiatric disorders.

SNP							Screening			Replication			Meta analysis		
Gene	CHR	SNP	BP ^a	type	A1 ^b	A2 ^c	MAF	P value	OR	MAF	P value	OR	P value	OR	
<i>CSNK1D</i>	17	rs9901910	77791546	3' region	G	C	Control	0.27							
							BP	0.25	0.26	0.93					
							SCZ	0.26	0.48	0.95					
							MDD	0.29	0.14	1.14					
	17	rs3829773	77814724	intron	A	G	Control	0.08							
							BP	0.07	0.44	0.91					
							SCZ	0.09	0.26	1.14					
							MDD	0.07	0.39	0.87					
	17	rs4789846	77819084	intron	T	C	Control	0.26							
							BP	0.25	0.57	0.96					
							SCZ	0.25	0.65	0.97					
							MDD	0.29	0.068	1.17					
17	rs6502097	77879718	5' region intron (<i>SECTM1</i>)	C	G	Control	0.15			0.17					
						BP	0.17	0.030	1.19	0.16	0.61	0.94	0.53	1.11	
						SCZ	0.16	0.15	1.13						
						MDD	0.14	0.48	0.92						
<i>CSNK1E</i>	22	rs135745	37013833	3' region	C	G	Control	0.24							
							BP	0.25	0.39	1.06					
							SCZ	0.26	0.12	1.12				0.095 ^d	1.26 ^d
							MDD	0.21	0.08	0.85					
	22	rs2075984	37021085	intron	C	A	Control	0.47			0.45				
							BP	0.47	0.81	0.99					
							SCZ	0.43	0.0091	0.85	0.45	0.63	0.98	0.21	0.92
							MDD	0.45	0.36	0.93					
	22	rs3890379	37022576	intron	G	A	Control	0.14							
							BP	0.16	0.052	1.17					
							SCZ	0.15	0.49	1.06					
							MDD	0.14	0.69	0.96					
	22	rs6001093	37031589	intron	C	T	Control	0.09							
							BP	0.10	0.12	1.16					
							SCZ	0.08	0.18	0.86					
							MDD	0.09	0.92	0.99					
	22	rs135757	37033849	intron	A	G	Control	0.23							
							BP	0.22	0.74	0.98					
							SCZ	0.22	0.67	0.97					
							MDD	0.22	0.57	0.95					
22	rs135764	37040608	intron	A	G	Control	0.16								
						BP	0.16	0.77	0.98						
						SCZ	0.15	0.48	0.94						
						MDD	0.17	0.48	1.08						
22	rs1997644	37045418	5' region	A	G	Control	0.38								
						BP	0.36	0.051	0.89						
						SCZ	0.38	0.89	0.99						
						MDD	0.37	0.49	0.95						

MAF = minor allele frequency, OR = odds ratio, BP = bipolar disorder, SCZ = schizophrenia, MDD = major depressive disorder.

^a Based upon hg19.

^b A1: minor allele based upon whole sample.

^c A2: major allele based upon whole sample.

^d Results from our screening sample and Huang's data [7].

observed (Table 1). Finally, we conducted a meta-analysis using the screening and replication samples. However, no associations were detected ($P=0.21$ and 0.53 for rs2075984 and rs6502097, respectively), thus providing no evidence that supports the association between the common SNPs in *CSNK1E* with SCZ or *CSNK1D* with BD (Table 1 and Supplementary Table 1).

4. Discussion

In this study, our results could not support evidence for an association between two casein 1 genes (*CSNK1D* and *CSNK1E*) and major psychiatric disorders (BD, SCZ and MDD). Four and seven tagging SNPs in *CSNK1D* and *CSNK1E*, respectively, were included in our study based upon linkage disequilibrium. In addition, an

imputation analysis was conducted to achieve full-range coverage, but none of the analyzed SNPs showed more significant P values than the signals observed at rs2075984 for SCZ or rs6502097 for BD, which are both SNPs that did not reach statistical significance in the final meta-analysis for SCZ and BD (Supplementary Figs. 3 and 4). We also could not replicate the previous finding of significant association of SNP with SCZ (rs135745) in our dataset. One possible explanation is that the discrepancy might be derived from the population difference between Japanese and Chinese population.

Recent genome-wide association studies (GWASs) suggest that the effect size for psychiatric disorders is low; for example, the effect sizes for SNPs with genome-wide significance range from 1.13 (0.88) to 1.14 for BD [12] and 1.09 to 1.22 for SCZ [18]. Although our approach was based upon candidate genes and assumes a

higher prior probability for association, a larger sample for replication samples is required. Our sample size for screening the dataset was relatively large, and the power analysis suggested that the samples had 99.9% power for BD, 99.7% for MDD and 99.9% for SCZ to detect a significant association (assuming a relaxed OR of 1.5) of risk with 15% minor allele frequency under an additive model (type I error rate = 0.05). However, our replication datasets, especially for rs6502097 in BD, had only 35% power, if the same OR detected in the screening analysis and the same conditions are assumed [13], indicated that a more conclusive result will be reported with a larger sample.

In addition, following limitation should be considered. First, we did not evaluate gene–gene interaction: Because the clock genes have been shown to form complicated pathways centering on the core negative feedback loop, such interaction among clock genes is presumably an important factor for developing psychiatric disorders. Following this concept, a genetic study found significant association between three circadian genes including *CSNK1E* and *BD* demonstrating a multi-locus interaction [15]. Therefore, epistasis test [15] or pathway-based analysis [6] concerning the pathogenesis of the whole circadian rhythm system should be conducted. Second, our sample sets were collected from multiple areas of Japan, thus likely to have genetic heterogeneity, which could skew the results in the first-set screening samples.

In conclusion, these results could not support the genetic variants in *CSNK1D* and *CSNK1E* as a susceptibility factor for major psychiatric disorders in the Japanese population. Although our sample has moderate power to detect association, further sample size and sophisticated and robust analytic strategies will be required for conclusive result.

Acknowledgements

We thank Ms. M. Miyata and Ms. M. Aizawa for their technical support. This work was supported by research grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Ministry of Health, Labor and Welfare of Japan; Academic Frontier Project for Private Universities, Comparative Cognitive Science Institutes; Core Research for Evolutional Science and Technology; Uehara Memorial Foundation; SENSHIN Medical Research Foundation; Takeda Science Foundation; Novartis Foundation, Japan; and Strategic Research Program for Brain Sciences of the MEXT of Japan.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.neulet.2012.08.070>.

References

- [1] C.D. Bryant, M.E. Graham, M.G. Distler, M.B. Munoz, D. Li, P. Vezina, G. Sokoloff, A.A. Palmer, A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine, *Psychopharmacology* 203 (2009) 703–711.
- [2] G. Chen, L.D. Huang, Y.M. Jiang, H.K. Manji, The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3, *Journal of Neurochemistry* 72 (1999) 1327–1330.
- [3] F. Desdouts, J.C. Siciliano, P. Greengard, J.A. Girault, Dopamine- and cAMP-regulated phosphoprotein DARPP-32: phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin, *Proceedings of the National Academy of Sciences of the United States of America* 92 (1995) 2682–2685.
- [4] B. Etain, V. Milhiet, F. Bellivier, M. Leboyer, Genetics of circadian rhythms and mood spectrum disorders, *European Neuropsychopharmacology* 21 (Suppl. 4) (2011) S676–S682.
- [5] A.G. Harvey, Sleep and circadian functioning: critical mechanisms in the mood disorders? *Annual Review of Clinical Psychology* 7 (2011) 297–319.
- [6] P. Holmans, E.K. Green, J.S. Pahwa, M.A. Ferreira, S.M. Purcell, P. Sklar, M.J. Owen, M.C. O'Donovan, N. Craddock, Gene ontology analysis of GWA study data sets provides insights into the biology of bipolar disorder, *American Journal of Human Genetics* 85 (2009) 13–24.
- [7] Y. Huang, J. Li, L. Wu, Q. Jin, X. Zhao, G. Zhu, Association between a casein kinase 1 epsilon gene polymorphism and schizophrenia in a Chinese Han population, *Journal of Molecular Neuroscience* 47 (2012) 470–474.
- [8] D.F. Kripke, C.M. Nievergelt, E. Joo, T. Shekhtman, J.R. Kelsoe, Circadian polymorphisms associated with affective disorders, *Journal of Circadian Rhythms* 7 (2009) 2.
- [9] E.W. Lamont, D.L. Coutu, N. Cermakian, D.B. Boivin, Circadian rhythms and clock genes in psychotic disorders, *Israel Journal of Psychiatry and Related Sciences* 47 (2010) 27–35.
- [10] E.W. Lamont, D. Legault-Coutu, N. Cermakian, D.B. Boivin, The role of circadian clock genes in mental disorders, *Dialogues in Clinical Neuroscience* 9 (2007) 333–342.
- [11] H. Lee, R. Chen, Y. Lee, S. Yoo, C. Lee, Essential roles of CK1delta and CK1epsilon in the mammalian circadian clock, *Proceedings of the National Academy of Sciences of the United States of America* 106 (2009) 21359–21364.
- [12] Psychiatric GWAS Consortium Bipolar Disorder Working Group, Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near *ODZ4*, *Nature Genetics* 43 (2011) 977–983.
- [13] S. Purcell, S.S. Cherny, P.C. Sham, Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits, *Bioinformatics* 19 (2003) 149–150.
- [14] S. Purcell, B. Neale, K. Todd-Brown, L. Thomas, M.A. Ferreira, D. Bender, J. Maller, P. Sklar, P.L. de Bakker, M.J. Daly, P.C. Sham, PLINK: a tool set for whole-genome association and population-based linkage analyses, *American Journal of Human Genetics* 81 (2007) 559–575.
- [15] J. Shi, J.K. Wittke-Thompson, J.A. Badner, E. Hattori, J.B. Potash, V.L. Willour, F.J. McMahon, E.S. Gershon, C. Liu, Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythm, *American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics* 147B (2008) 1047–1055.
- [16] V. Soria, E. Martinez-Amoros, G. Escaramis, J. Valero, R. Perez-Egea, C. Garcia, A. Gutierrez-Zotes, D. Puigdemont, M. Bayes, J.M. Crespo, L. Martorell, E. Vilella, A. Labad, J. Vallejo, V. Perez, J.M. Menchon, X. Estivill, M. Gratacos, M. Urretavizcaya, Differential association of circadian genes with mood disorders: *CRY1* and *NPAS2* are associated with unipolar major depression and *CLOCK* and *VIP* with bipolar disorder, *Neuropsychopharmacology* 35 (2010) 1279–1289.
- [17] A. Takano, M. Uchiyama, N. Kajimura, K. Mishima, Y. Inoue, Y. Kamei, T. Kitajima, K. Shibui, M. Katoh, T. Watanabe, Y. Hashimoto, T. Nakajima, Y. Ozeki, T. Hori, N. Yamada, R. Toyoshima, N. Ozaki, M. Okawa, K. Nagai, K. Takahashi, Y. Isojima, T. Yamauchi, T. Ebisawa, A missense variation in human casein kinase I epsilon gene that induces functional alteration and shows an inverse association with circadian rhythm sleep disorders, *Neuropsychopharmacology* 29 (2004) 1901–1909.
- [18] The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, Genome-wide association study identifies five new schizophrenia loci, *Nature Genetics* 43 (2011) 969–976.
- [19] A. Tuunainen, D.F. Kripke, T. Endo, Light therapy for non-seasonal depression, *Cochrane Database of Systematic Reviews* (2004) CD004050.
- [20] J. Veenstra-VanderWeele, A. Qaadir, A.A. Palmer, E.H. Cook Jr., H. de Wit, Association between the casein kinase 1 epsilon gene region and subjective response to D-amphetamine, *Neuropsychopharmacology* 31 (2006) 1056–1063.
- [21] D.K. Welsh, J.S. Takahashi, S.A. Kay, Suprachiasmatic nucleus: cell autonomy and network properties, *Annual Review of Physiology* 72 (2010) 551–577.
- [22] K. Wulff, D.J. Dijk, B. Middleton, R.G. Foster, E.M. Joyce, Sleep and circadian rhythm disruption in schizophrenia, *British Journal of Psychiatry* (2011).
- [23] Y. Xu, Q.S. Padiath, R.E. Shapiro, C.R. Jones, S.C. Wu, N. Saigoh, K. Saigoh, L.J. Ptacek, Y.H. Fu, Functional consequences of a CK1delta mutation causing familial advanced sleep phase syndrome, *Nature* 434 (2005) 640–644.
- [24] L. Yin, J. Wang, P.S. Klein, M.A. Lazar, Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock, *Science* 311 (2006) 1002–1005.
- [25] M. Zhou, H. Rebholz, C. Brocia, J.L. Warner-Schmidt, A.A. Fienberg, A.C. Nairn, P. Greengard, M. Flajolet, Forebrain overexpression of CK1delta leads to down-regulation of dopamine receptors and altered locomotor activity reminiscent of ADHD, *Proceedings of the National Academy of Sciences of the United States of America* 107 (2010) 4401–4406.

Resequencing and Association Analysis of the *KALRN* and *EPHBI* Genes And Their Contribution to Schizophrenia Susceptibility

Itaru Kushima^{1,2}, Yukako Nakamura^{1,2}, Branko Aleksic^{1,2}, Masashi Ikeda^{2,3}, Yoshihito Ito^{1,2}, Tomoko Shiino^{1,2}, Tomo Okochi^{2,3}, Yasuhisa Fukuo^{2,3}, Hiroshi Ujike⁴, Michio Suzuki^{2,5}, Toshiya Inada⁶, Ryota Hashimoto^{2,7,8}, Masatoshi Takeda^{7,8}, Kozo Kaibuchi^{2,9}, Nakao Iwata^{2,3,*}, and Norio Ozaki^{1,2}

¹Department of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya, Japan; ²Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Tokyo, Japan; ³Department of Psychiatry, School of Medicine, Fujita Health University, Toyoake, Aichi 470-1192, Japan; ⁴Department of Neuropsychiatry, Graduate School of Medicine, Okayama University, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ⁵Department of Neuropsychiatry, Graduate School of Medicine and Pharmaceutical Sciences, Toyama University, Toyama, Japan; ⁶Seiwa Hospital, Institute of Neuropsychiatry, Tokyo, Japan; ⁷Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Kanazawa University and Hamamatsu University School of Medicine, Osaka, Japan; ⁸Department of Psychiatry, Graduate School of Medicine, Osaka University, Osaka, Japan; ⁹Department of Cell Pharmacology, Graduate School of Medicine, Nagoya University, Nagoya, Japan

*To whom correspondence should be addressed; tel: +81-562-93-9250; fax: +81-562-93-1831, e-mail: nakao@fujita-hu.ac.jp

Background: Our genome-wide association study of schizophrenia found association signals at the Kalirin gene (*KALRN*) and EPH receptor B1 gene (*EPHBI*) in a Japanese population. The importance of these synaptogenic pathway genes in schizophrenia is gaining independent supports. Although there has been growing interest in rare (<1%) missense mutations as potential contributors to the unexplained heritability of schizophrenia, there are no population-based studies targeting rare (<1%) coding mutations with a larger effect size (eg, OR >1.5) in *KALRN* or *EPHBI*. **Methods and Results:** The present study design consisted of 3 phases. At the discovery phase, we conducted resequencing analyses for all exon regions of *KALRN* and *EPHBI* using a DNA microarray-based method. Seventeen rare (<1%) missense mutations were discovered in the first sample set (320 schizophrenic patients). After the prioritization phase based on frequencies in the second sample set (729 cases and 562 controls), we performed association analyses for each selected mutation using the third sample set (1511 cases and 1517 controls), along with a combined association analysis across all selected mutations. In *KALRN*, we detected a significant association between schizophrenia and P2255T (OR = 2.09, corrected $P = .048$, 1 tailed); this was supported in the combined association analysis (OR = 2.07, corrected $P = .006$, 1 tailed). We found no evidence of association of *EPHBI* with schizophrenia. *In silico* analysis indicated the functional relevance of these rare missense mutations. **Conclusion:** We provide evidence that multiple rare (<1%) missense mutations in *KALRN* may be genetic risk factors for schizophrenia.

Key words: synaptogenic pathway/rare missense mutations/GWAS/Japanese population

Introduction

Schizophrenia is a genetically heterogeneous disorder with heritability estimated at up to 80%.¹ According to a recent simulation based on genome-wide association study (GWAS) datasets, a highly polygenic model involving a number of common variants of very small effect may explain more than one-third of the total variation in risk of schizophrenia.² On the other hand, interest has been growing in rare variants as potential contributors to the unexplained heritability of schizophrenia.³ This is partly triggered by recent studies establishing an important role for rare genomic copy number variants (CNVs) in the etiology of schizophrenia.⁴ Another potential genetic variation to explain the remaining heritability is rare missense mutations. Kryukov et al⁵ reported that ~20% of new (de novo) missense mutations in humans result in a loss of function, whereas ~53% have mildly deleterious effects and ~27% are effectively neutral with respect to phenotype by a combined analysis of mutations causing human Mendelian diseases, mutations driving human-chimpanzee sequence divergence, and systematic data on human genetic variation. Their results were supported by an independent study.⁶ Because the pressure of purifying selection acting on the mildly deleterious mutations is weak, their cumulative high frequency in the human population is being maintained

by “mutation-selection balance.” This provides support to a speculation that the accumulation of mildly deleterious missense mutations in individual human genomes can be a genetic basis for complex diseases.⁵ The importance of rare missense mutations in schizophrenia is demonstrated by a study of the *ABCA13* gene in which multiple rare (<1%) coding variants were associated with schizophrenia.⁷

We recently performed a GWAS for schizophrenia in a Japanese population.⁸ Although single locus analysis did not reveal genome-wide support for any locus, a shared polygenic risk of schizophrenia between the Japanese and the Caucasian samples was confirmed. In our GWAS, association signals were detected at the regions of the Kalirin gene (*KALRN*) on 3q21.2 and the EPH receptor B1 gene (*EPHBI*) on 3q21-q23, both of which are in the same synaptogenic pathway⁹ (supplementary figure S1). Associations of each gene with schizophrenia have recently received support from independent GWASs in different populations.^{10,11} Furthermore, a rare de novo CNV overlapping with the *EPHBI* gene locus was detected in a patient with schizophrenia.¹²

KALRN is a large neuronal dual Rho guanine nucleotide exchange factor (GEF) that activates small guanosine triphosphate-binding proteins of the Rho family, including Rac1.¹³ This activation enables *KALRN* to regulate neurite initiation, axonal growth, dendritic morphogenesis, and spine morphogenesis. Consistent with its biological function, *KALRN* is a key factor responsible for reduced densities of dendritic spines on pyramidal neurons in the dorsolateral prefrontal cortex (DLPFC)¹⁴ observed in postmortem brains from schizophrenic patients. The messenger RNA expression level of *KALRN* is significantly reduced in DLPFC of patients with schizophrenia and strongly correlated with spine density.¹⁵ In addition, *KALRN*-knockout mice not only exhibit spine loss and reduced glutamatergic transmission in the frontal cortex but also schizophrenia-like phenotypes including robust deficits in working memory, sociability, prepulse inhibition, and locomotor hyperactivity reversible by clozapine, an atypical antipsychotic.¹⁶ These synaptic and behavioral dysfunctions are apparent during young adulthood in mice (12 weeks old), which coincides with the onset of schizophrenia in patients. Notably, Disrupted-in-Schizophrenia 1, a prominent schizophrenia risk factor, was shown to be involved in the maintenance of spine morphology and function by regulating access of *KALRN* to Rac1.¹⁷ *EPHBI* belongs to a receptor tyrosine kinase family and controls multiple aspects of neuronal development, including synapse formation and maturation, as well as synaptic structural and functional plasticity. In neurons, activation of EphB receptors by its ligand B-type ephrins induces the rapid formation and enlargement of dendritic spines, as well as rapid synapse maturation. One of the downstream effectors of ephrinB/EphB signaling is *KALRN*. In

young hippocampal neurons, *KALRN* is reported to play an important role in the maturation of synapses induced by trans-synaptic ephrinB/EphB signaling.¹⁸

According to the above-mentioned study,⁵ most missense mutations with a frequency of <1% are mildly deleterious, indicating that a low frequency of missense mutation per se can serve as a strong predictor of a deleterious effect of variants. Therefore, the working hypothesis of the present study is that rare (<1%) missense or nonsense mutations with a larger effect size (eg, OR >1.5) in *KALRN* and *EPHBI* may be genetic risk factors for schizophrenia. Recently, a DNA microarray-based resequencing method has been developed to enable accurate and rapid resequencing analysis of candidate genes.¹⁹ Using this system, we conducted resequencing analyses for all exon regions of *KALRN* and *EPHBI* in 320 schizophrenic patients and found evidence that rare (<1%) missense mutations in *KALRN* are significantly associated with schizophrenia using the 3-phase study design.

Methods and Materials

Subjects

Three sample sets were used in this study. The first sample set, comprising 320 schizophrenic patients (mean age, 54.2 ± 14.1 years, 49.1% male), with long-term hospitalization for severe symptoms, was used to search for rare missense or nonsense mutations. We used the first sample set for mutation screenings because patients with extreme phenotypes (severe symptoms) can be expected to carry more deleterious mutations.²⁰ The second sample set, including 729 cases (45.4 ± 15.1 years, 52.2% male) and 562 controls (44.0 ± 14.4 years, 49.8% male), was used to prioritize detected functional variants for subsequent association analyses. The third sample set, including 1511 cases (45.9 ± 14.0 years, 49.6% male) and 1517 controls (46.0 ± 14.6 years, 49.6% male), was used for association analyses. Age and gender were matched in the second and third sample sets, respectively. All patients were diagnosed according to *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition*, criteria, and controls were evaluated using unstructured interviews to exclude individuals with history of mental disorders. Detailed information regarding diagnostic procedures is available elsewhere.²¹ All subjects were ethnically Japanese and provided written informed consent. This study was approved by the ethics committees at each participating university.

Array Design for Resequencing Analyses

We used the Affymetrix GeneChip CustomSeq Resequencing Array (Affymetrix, Santa Clara, California) for exon sequencing in the first sample set. These arrays rely on allele-specific hybridization for determining DNA

sequence.¹⁹ Each individual nucleotide of both the sense and the antisense DNA strands is interrogated with four 25-mer probes that differ only with respect to the central position (A, C, G, and T). According to Affymetrix's Custom-Seq Array Design Guide, we designed arrays covering all exon regions of *KALRN* and *EPHBI* (Ensembl release 52 [Human CCDS set]; Transcript: ENST00000360013, ENST00000240874, and ENST00000291478 for *KALRN*; ENST00000398015 for *EPHBI*). Because the principle of the resequencing arrays is based on hybridization, it is necessary to avoid cross-hybridization for accurate resequencing. For this purpose, we removed repetitive elements and highly homologous sequences from the array design.

Array-Based Resequencing

The experiments were conducted according to the manufacturer's instructions (supplementary figure S2). Genomic DNA was extracted from peripheral blood using standard methods. To generate enough target-enriched subject material for hybridization to the arrays, we generated 47 and 14 amplicons per sample for *KALRN* and *EPHBI*, respectively, using long-range polymerase chain reaction (PCR). The PCR conditions were as follows: 94°C for 2 minutes followed by 30 cycles consisting of 94°C for 15 seconds, 68°C for 3 minutes, followed by a final extension of 68°C for 8 minutes, using TaKaRa LA Taq™ (Takara Bio, Otsu, Shiga, Japan). Each PCR product was quantified using PicoGreen (Molecular Probes, Eugene, Oregon), pooled in an equimolar fashion. The PCR products were then purified, fragmented, labeled, and hybridized to the arrays, following the protocol. Finally, the arrays were washed and stained using the GeneChip Fluidics Station 450 (Affymetrix) and scanned using the GeneChip Scanner 3000 (Affymetrix). The data were analyzed using the GeneChip Operating Software (GCOS; Affymetrix), the GeneChip Sequence Analysis Software (GSEQ; Affymetrix), and SeqC (JSI Medical Systems, Kippenheim, Germany; <http://www.jsi-medisys.de/html/products/SeqC/SeqC.htm>) to automate the generation of sequence and genotype calls from the intensity data. In this study, around 17 kb was sequenced per sample, meaning that more than 5.4 Mb was sequenced in total. All missense mutations presented in this study were confirmed using both Sanger sequencing and Custom TaqMan SNP genotyping assays (Applied Biosystems, Foster City, California).

Association Analysis of Each Missense Mutation

Although the rare (<1%) missense mutations were originally discovered among 320 schizophrenic patients, it was possible that a portion of them might have neutral or protective effects.⁵ In addition, it was necessary to reduce the number of statistical tests for multiple comparison problems. To accomplish this, we prioritized rare

(<1%) deleterious variants for subsequent association analyses based on the frequencies in the second case-control sample set because rare deleterious variants relevant to schizophrenia can be assumed to have higher frequency in cases than in controls. The criteria for prioritization were as follows: (1) frequencies of mutations were <1% in controls and (2) frequencies of mutations were higher in cases (ie, OR > 1). Mutations not detected in the second sample set were not followed up in this analysis. The frequencies of such mutations can be so low (<0.0005) that the results of association analyses are unlikely to be statistically significant in our sample size. For mutations meeting the above criteria, we conducted association analyses with schizophrenia using the third sample set. Genotyping was conducted by Custom TaqMan SNP genotyping assays (Applied Biosystems). For quality control, samples with missing call rates of 10% or higher were excluded from the analyses.

Combined Association Analyses

In general, it is difficult to establish an association of a rare mutation with a phenotype because statistical power is limited by low population frequency and because the number of rare variants requires a strict multiple test correction. Therefore, we conducted combined association analyses across rare mutations observed in each gene in the third sample set, comparing the number of mutations in cases with the number in controls. The criteria for mutations included in these analyses were same as the above criteria with 1 exception: Mutations not detected in the second sample set were included in the combined association analyses.

In Silico Analysis

The potential influence of missense mutations was evaluated using PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) and²² PMut (<http://mmb2.pcb.ub.es:8080/PMut/>)²³ softwares. PolyPhen-2 uses 8 sequence-based and 3 structure-based predictive features and compares a property of the wild-type allele and the corresponding property of the mutant allele. PolyPhen-2 trained on HumDiv datasets is reported to achieve true positive prediction rates of 92% with a false-positive rate of 20%.²² A mutation is appraised qualitatively as benign, possibly damaging, or probably damaging based on naive Bayes posterior probability that a given mutation is damaging. PMut also allows the fast and accurate prediction (~80% success rate in humans) of the pathological character of missense mutations based on the use of neural networks. The final output is a pathogenicity index ranging from 0 to 1 (indexes >0.5 signal pathological mutations).

We also examined evolutionary conservation of the mutated residues and surrounding amino acids. Multiple sequence alignment of human *KALRN* or *EPHBI* with 6 orthologs was performed for this purpose.

Power Calculation

Power calculation was performed with a power calculator called CaTS (<http://www.sph.umich.edu/csg/abecasis/CaTS/>).²⁴ Power was estimated under the following parameter assumptions with respect to association test statistics: genetic relative risk = 2, prevalence of disease = 0.01, risk allele frequency = the values frequency observed in controls, and $\alpha = .05$; a multiplicative model was used.

Statistical Analysis

For the association analysis of each variant, Fisher exact test was used to examine whether rare deleterious variants were significantly overrepresented in the patient group rather than the control group.

A combined association test was performed following a previous study.⁷ In brief, to account for variable sample size, sample size was adjusted to $N=n/(\sum(1/N_i))$, where N_i is the sample size at the i th variant, and n is the number of variants. The number of observed variants was adjusted as $\sum(pi) \times N$, where pi is the frequency of the i th variant. Fisher exact test was used in this test as well to examine an overrepresentation of rare deleterious missense mutations in the patient group rather than control group.

All statistical tests were 1 tailed, and a P value less than 0.05 was considered significant. Bonferroni correction was used for solving multiple testing problems.

Results

Discovery of Mutations

We detected 12 and 6 missense mutations with a frequency of <5% in *KALRN* and *EPHBI*, respectively, among 320 cases in the first sample set (table 1). All but 2 mutations (N2973S in *KALRN* and T981M in *EPHBI*) were novel. All mutations were validated by both Sanger sequencing and Custom TaqMan SNP genotyping assays. In the first sample set, 2 patients were compound heterozygotes for rare missense mutations in the 2 genes. One patient had R410H in *KALRN* and R905C in *EPHBI*. The other had A2382V in *KALRN* and D375N in *EPHBI*. There were no clinical characteristics shared between these patients. No nonsense mutations were identified in this study.

Association Analysis of Each Missense Mutation

In the prioritization phase using the second sample set, T1207M and P2255T in *KALRN* and R637C and R905C in *EPHBI* showed a higher frequency in cases than in controls (table 1). Seven missense mutations (R410H, Q770K, and A2382V in *KALRN* and F151S, D375N, D577N, and T981M in *EPHBI*) were not detected. The frequency of P1695Q was more than 4% both in cases and in controls. Based on our criteria, we selected 4 missense mutations (T1207M and

P2255T in *KALRN* and R637C and R905C in *EPHBI*) for subsequent association analyses using the third sample set.

In the third phase, P2255T showed a nominally significant association with schizophrenia (OR = 2.09, $P = .012$) in the third sample set (table 2). This remained significant after correction for multiple testing of 4 variants (corrected $P = .048$). T1207M in *KALRN* and R637C and R905C in *EPHBI* were also more frequent in cases, although differences were not significant.

We excluded mutations not detected in the second sample set from this analysis. This was supported by a power analysis showing that the third sample set had only 10% power in analysis of very rare mutations.

Combined Association Analysis

In addition to 4 mutations (T1207M and P2255T in *KALRN* and R637C and R905C in *EPHBI*), 7 very rare mutations (R410H, Q770K, and A2382V in *KALRN* and F151S, D375N, D577N, and T981M in *EPHBI*), which were not detected in the second samples set, were included in the combined association analysis. A global comparison of the frequencies of 5 selected mutations in *KALRN* between cases and controls in the third sample set showed a significant increase in frequency in schizophrenic patients (OR = 2.07, $P = .003$) (table 3). This remained significant after correction for multiple testing (corrected $P = .006$). On the other hand, a global comparison of the frequencies of 6 selected mutations in *EPHBI* did not show a significant difference (OR = 1.09, $P = .438$).

In Silico Analysis

Results of *in silico* analysis are shown in table 4. All missense mutations but A2382V in *KALRN* were predicted to have functional relevance by PolyPhen-2 or PMut software.

A multiple alignment of the region of *KALRN* or *EPHBI* containing rare missense mutations with 6 orthologs is shown in table 4. Most of the rare missense mutations showed a high degree of amino acid conservation in different species.

Discussion

In this study, we conducted resequencing analyses for the 2 synaptogenic pathway genes (*KALRN* and *EPHBI*) in schizophrenia using a DNA microarray-based method. After resequencing more than 5.4 Mb, we discovered 17 rare (<1%) missense mutations in *KALRN* or *EPHBI* and detected a significant association between schizophrenia and P2255T in *KALRN*, as well as in the combined association analysis for *KALRN*. These findings are consistent with an estimation that most rare (<1%) missense mutations are mildly deleterious and are associated with a heterozygous fitness loss.⁵

Table 1. *KALRN* And *EPHB1* Missense Mutations Identified in The First Sample Set And Their Frequencies in The Second Sample Set

Gene	Genomic Position	Base Change	dbSNP Reference	AA Change	First Sample Set		Second Sample Set				OR >1
					Homo	Hetero	Genotype Counts		Mutation Frequency		
							SCZ	CONT	SCZ	CONT	
KALRN	125527659	G → A	ss250607852	R410H	0	1	0/0/701	0/0/541	0	0	
KALRN	125531474	T → A	ss250607853	L452Q	0	1	0/1/709	0/2/541	0.0007	0.0018	
KALRN	125600376	C → A	ss250607854	Q770K	0	1	0/0/706	0/0/544	0	0	
KALRN	125656787	C → T	ss250607855	T1207M	0	1	0/2/705	0/1/542	0.0014	0.0009	+
KALRN	125764534	C → A	ss250607856	P1695Q	0	1	0/59/636	1/44/492	0.0425	0.0428	
KALRN	125764599	A → T	ss250607857	M1717L	0	1	0/0/705	0/1/540	0	0.0009	
KALRN	125860927	G → A	ss250607858	R2049K	0	1	0/1/696	0/1/540	0.0007	0.0009	
KALRN	125873259	C → A	ss250607859	P2255T	0	7	1/14/684	0/7/536	0.0114	0.0064	+
KALRN	125873289	C → T	ss250607860	P2265S	1	0	0/6/701	0/7/533	0.0042	0.0065	
KALRN	125873382	G → T	ss250607861	G2296C	0	1	0/1/703	0/1/542	0.0007	0.0009	
KALRN	125876103	C → T	ss250607862	A2382V	0	1	0/0/697	0/0/540	0	0	
KALRN	125920964	A → G	rs16835896	N2973S	0	3	0/3/698	0/6/538	0.0021	0.0055	
EPHB1	136153231	T → C	ss252863894	F151S	0	1	0/0/710	0/0/543	0	0	
EPHB1	136334407	G → A	ss252863895	D375N	0	1	0/0/708	0/0/544	0	0	
EPHB1	136368508	G → A	ss252863896	D577N	0	1	0/0/707	0/0/544	0	0	
EPHB1	136394134	C → T	ss252863897	R637C	0	2	1/1/707	0/2/541	0.0021	0.0018	+
EPHB1	136450890	C → T	ss252863898	R905C	0	3	0/9/695	0/1/543	0.0064	0.0009	+
EPHB1	136460639	C → T	rs56186270	T981M	0	2	0/0/706	0/0/541	0	0	

Note: Genomic position based on NCBI build 36, chromosome 3. Amino acid changes based on NCBI Reference Sequence NP_001019831.2 (2986 aa) for *KALRN* and NP_004432.1 (984 aa) for *EPHB1*. All but N2973S (rs16835896) and T981M (rs56186270) are novel. AA change, amino acid change; dbSNP, Single Nucleotide Polymorphism Database; Homo, homozygote; Hetero, heterozygote; SCZ, schizophrenia; CONT, control; NCBI, National Center for Biotechnology Information.

Schizophrenia is a genetically heterogeneous disorder, with both very rare variants with a high effect size (eg, CNVs in 1q21.1, 15q13.3) and common variants with a low effect size (eg, rs1344706 in *ZNF804A*) involved in its genetic architecture. In this frequency-effect size spectrum, P2255T (OR: ~2, risk allele frequency in controls: ~0.005) is located between the CNV in 1q21.1 (OR: ~10, frequency in controls: ~0.0001)²⁵ and rs1344706[T] in *ZNF804A* (OR: ~1.1, risk allele frequency in controls: ~0.6),²⁶ both of which have been recently associated with schizophrenia. The relatively modest effect size of P2255T compared with that of the above CNVs can be attributable to the difference in the effect of each variant on gene(s): Although CNVs strongly influence the

expression of multiple genes, missense mutations in *KALRN* are presumed to have limited effects on *KALRN* function. P2255T is located in the evolutionally conserved proline-rich region between the C-terminal GEF and SH3 domains²⁷ and is surrounded by 2 nearby phosphorylation sites (S2237 and S2262), according to Human Protein Reference Database (<http://www.hprd.org/index.html>)²⁸ (figure 1). *In silico* analysis with PhosphoMotif Finder²⁹ shows that T2255 itself can be recognized and phosphorylated by many kinases, suggesting functional implications of P2255T (figure 1). In addition, *in silico* analysis predicts that phosphorylation of T2255 will induce that of nearby S2253. Thus, P2255T may greatly change the phosphorylation status in a narrow

Table 2. Association Analyses of Each Missense Mutation in the Third Sample Set

	AA Change	Third Sample Set				OR	P Value
		Genotype Counts		Mutation Frequency			
		SCZ	CONT	SCZ	CONT		
KALRN	T1207M	0/7/1477	0/3/1482	0.0024	0.0010	2.34	.171
KALRN	P2255T	0/31/1448	0/15/1473	0.0105	0.0050	2.09	.012
EPHB1	R637C	0/4/1477	0/4/1478	0.0014	0.0014	1.00	.636
EPHB1	R905C	0/15/1458	0/12/1466	0.0051	0.0041	1.26	.347

Note: Abbreviations are explained in the first footnote to table 1. P values were calculated by Fisher exact test (1 tailed).

Table 3. Combined Association Analysis in The Third Sample Set

Gene	AA Change	Third Sample Set				Combined Analysis	
		Genotype Counts		Mutation Frequency		Gene Based	
		SCZ	CONT	SCZ	CONT	OR	P value
KALRN	R410H	0/0/1481	0/0/1484	0	0	2.07	.003
KALRN	Q770K	0/0/1486	0/0/1490	0	0		
KALRN	T1207M	0/7/1477	0/3/1482	0.0024	0.0010	1.09	.438
KALRN	P2255T	0/31/1448	0/15/1473	0.0105	0.0050		
KALRN	A2382V	0/7/1473	0/4/1480	0.0024	0.0013		
EPHB1	F151S	0/0/1478	0/0/1484	0	0		
EPHB1	D375N	0/0/1483	0/0/1490	0	0		
EPHB1	D577N	0/0/1486	0/2/1483	0	0.000673		
EPHB1	R637C	0/4/1477	0/4/1478	0.0014	0.0014	0.0041	0.0041
EPHB1	R905C	0/15/1458	0/12/1466	0.0051	0.0041		
EPHB1	T981M	0/5/1481	0/4/1484	0.0017	0.0013		

Note: Abbreviations are explained in the first footnote to table 1. P values were calculated by Fisher exact test (1 tailed).

region between the C-terminal GEF and SH3 domain. A protein with multiple phosphorylated sites like KALRN can be assumed to have an exponential number of phospho-forms, and individual phospho-forms may have distinct biological effects. The diffuse distribution of these phospho-forms at steady state enables the phosphoproteome to encode information and flexibly respond to varying demands.³⁰ Thus, it is conceivable that P2255T may influence such plasticity in KALRN by changing the number of phosphorylated sites. Interestingly, detailed examination of clinical information from the first sample set, which was uniquely available to us, revealed that con-

genital or early-onset vascular disease was observed in 5 of 7 cases with P2255T (supplementary table S1). Because KALRN may represent a candidate gene for vascular diseases,^{31,32} it is tempting to speculate that P2255T may be a potential risk factor for vascular disease.

In addition to P2255T, we detected multiple rare (<1%) missense mutations in KALRN or EPHB1. Such variants are not sufficiently frequent to be covered by GWAS nor do they have sufficiently large effect sizes to be detected by linkage analysis in family studies. For modest effect sizes, it is suggested that association testing may require composite tests of overall mutational load,

Table 4. Results of *In Silico*/Conservation Analysis

KALRN		R410H	Q770K	T1207M	P2255T	A2382V
Analysis		Probably	Probably	Probably	Benign	Benign
PolyPhen-2		damaging	damaging	damaging		
PMut		Pathological	Neutral	Pathological	Pathological	Neutral
Conservation	Human (NP_001019831.2)	LDERSTI	IFLQLRI	IHATEIR	RSQPARL	SILAPLT
analysis	Chimpanzee (XP_516703.2)	LDERSTI	IFLQLRI	IHATEIR	RSQPARL	SILAPLT
	Dog (XP_535768.2)	LDERSTI	IFLQLRI	IHATEIR	RSQPSRV	SVLAPLT
	Cattle (XP_001790302.1)	LDERSTI	IFLQLRI	IHATEIR	RSQPARV	SILTPLT
	Mouse (XP_001481079.1)	LDERSTI	IFLQLRI	IHATEIR	RSQPPRV	SILAPLA
	Rat (NP_114451.1)	LDERSTI	IFLQLRI	IHATEIR	RSQPPRV	SILAPLT
EPHB1		F151S	D375N	D577N	R637C	R905C
Analysis		Benign	Probably	Possibly	Probably	Probably
PolyPhen-2			damaging	damaging	damaging	damaging
PMut		Pathological	Neutral	Neutral	Pathological	Pathological
Conservation	Human (NP_004432.1)	QVDFGGR	RCDDNVE	VYSDKLQ	YKGRCLK	LLDRSIP
analysis	Chimpanzee	QVDFGGR	RCDDNVE	LLVEQWQ	YKGRCLK	LLDRSIP
	(XP_001150963.1)					
	Dog (XP_542791.2)	QVDFGGR	RCDDNVE	VYSDKLQ	YKGRCLK	LLDRSIP
	Cattle (XP_614602.4)	QVDFGGR	RCDDNVE	VYSDKLQ	YKGRCLK	LLDRSIP
	Mouse (NP_775623.2)	QVDFGGR	RCDDNVE	AYSCKLQ	YKGRCLK	LLDRSIP
	Rat (XP_217250.1)	QVDFGGR	RCDDNVE	VYSDKLQ	YKGRCLK	LLDRSIP

Note: The bold are the mutated amino acids.




Fig. 1. Rare Missense Mutations in *KALRN* and Change in Phosphorylation Status by P2255T.

comparing frequencies of mutations of potentially similar functional effect in cases and controls. Thus, we also performed combined association analyses for *KALRN* or *EPHB1* and found evidence that multiple rare (<1%) missense mutations in *KALRN* as a whole are associated with schizophrenia. This finding is supported by *in silico* analyses showing that most of the mutations are predicted as being of functional relevance and that they are located in evolutionally conserved regions. In contrast, there were no significant differences in the cumulative frequencies of rare missense mutations in *EPHB1*. This might be due to a type II error. The cumulative frequency of rare mutations of *EPHB1* in controls is almost same as the one of *KALRN* in controls (0.0075 vs 0.0073), indicating that cumulative effect size of rare missense mutations in *EPHB1* may be smaller than the one in *KALRN*. In the mammalian genome, there are 5 different EphB receptors (EphB1, EphB2, EphB3, EphB4, and EphB6), with a high similarity at the amino acid level. Analysis of double and triple knockout mice lacking EphB1, EphB2, and EphB3 in different combinations revealed that EphBs have functional redundancy even though all these EphBs are responsible for spine morphogenesis and synapse formation to varying degrees.³³ This is in contrast with the drastic phenotypes observed in *KALRN*-knockout mice.¹⁶ Therefore, biological effects

of rare missense mutations in *EPHB1* may be compensated for by other intact *EPHBs*. This might lower the ORs of rare missense mutations in *EPHB1*. Given that all the mutations detected in *EPHB1* were predicted to have pathogenicity by PolyPhen-2 or PMut, a larger-scale case-control study with sufficient power may provide a significant result in a combined analysis for *EPHB1*.

One important aspect of the present study is that we found rare mutations associated with schizophrenia in the *KALRN* gene, in which GWASs detected association signals for schizophrenia. Several studies have recently reported the 1 gene may harbor both rare and common variants associated with the same diseases, including schizophrenia,³⁴ type 2 diabetes,³⁵ and hypertriglyceridemia.³⁶ Given that the cost of whole-genome sequencing is still high to search for rare mutations, resequencing analyses for genes with support from GWAS might be a better strategy for detection of rare mutations with larger effect size.

There are several limitations to this study. First, we could not conduct segregation analyses for mutations due to limited access to family members. Furthermore, given the modest risk (OR ~2), these mutations would show incomplete penetrance. In fact, it is reported that penetrance estimates of CNVs at 1q21.1 and 15q13.3,

both of which show higher ORs, are 0.061 and 0.074, respectively.²⁵ Therefore, a population-based study is a better choice to evaluate genetic associations for missense mutations with modest risk.³⁷ The second limitation is population stratification. Although a Japanese population is considered relatively homogenous, small population stratifications may have influenced our findings.³⁸ However, we believe that the recruitment of subjects in local regions minimized this concern. Third, we did not conduct functional analyses for detected missense mutations. The detailed effects of these mutations on the pathophysiology of schizophrenia need to be examined in a future study. Fourth, our resequencing analyses were not comprehensive in terms of the kind of variants and the number of genes. In other words, the present study did not cover indels or CNVs because of the methodological limitation of the DNA microarray-based method. Because these classes of variants could have a more profound effect on protein function, their genetic contribution to schizophrenia might be revealed in future studies. Also, as shown in *EPHBI*, it is assumed that a variety of molecules or pathways have a role in spine formation or synapse plasticity, which are impaired in patients with schizophrenia, to compensate for each other. A combined analysis of a large number of genes relevant for synaptic function might provide more robust evidence that rare missense mutations as a whole contribute to pathomechanisms of schizophrenia.

In conclusion, we provide the first evidence that multiple rare (<1%) missense mutations in *KALRN* may be genetic risk factors for schizophrenia. Further studies will be needed to examine the pathogenicity of these mutations from a biologic point of view.

Funding

This work was supported by research grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; Grant-in-Aid for Scientific Research on Pathomechanisms of Brain Disorders from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Academic Frontier Project for Private Universities, Comparative Cognitive Science Institutes; Core Research for Evolutional Science and Technology.

Supplementary Material

Supplementary material is available at <http://schizophreniabulletin.oxfordjournals.org>.

Acknowledgments

We sincerely thank the patients and healthy volunteers for their participation in this study. We

also thank Ryoko Ishihara and Junko Tsuda for technical assistance.

The authors report no biomedical financial interests or potential conflicts of interest.

References

1. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry*. 2003;60:1187–1192.
2. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009;460:748–752.
3. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. *Nature*. 2009;461:747–753.
4. Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdeletions associated with schizophrenia. *Nature*. 2008;455:232–236.
5. Kryukov GV, Pennacchio LA, Sunyaev SR. Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. *Am J Hum Genet*. 2007;80:727–739.
6. Boyko AR, Williamson SH, Indap AR, et al. Assessing the evolutionary impact of amino acid mutations in the human genome. *PLoS Genet*. 2008;4:e1000083.
7. Knight HM, Pickard BS, Maclean A, et al. A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression. *Am J Hum Genet*. 2009;85:833–846.
8. Ikeda M, Aleksic B, Kinoshita Y, et al. Genome-wide association study of schizophrenia in a Japanese population [published online ahead of print September 10, 2010]. *Biol Psychiatry*. doi: 10.1016/j.biopsych.2010.07.010.
9. Penzes P, Beeser A, Chernoff J, et al. Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rho-GEF kalirin. *Neuron*. 2003;37:263–274.
10. St Jean PL. Genes associated with schizophrenia identified using a whole genome scan. 2008. <http://www.freepatentsonline.com/y2008/0176240.html>. Accessed August 8, 2010.
11. Sullivan PF, Lin D, Tzeng JY, et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. *Mol Psychiatry*. 2008;13:570–584.
12. Xu B, Roos JL, Levy S, et al. Strong association of de novo copy number mutations with sporadic schizophrenia. *Nat Genet*. 2008;40:880–885.
13. Rabiner CA, Mains RE, Eipper BA. Kalirin: a dual Rho guanine nucleotide exchange factor that is so much more than the sum of its many parts. *Neuroscientist*. 2005;11:148–160.
14. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. *Arch Gen Psychiatry*. 2000;57:65–73.
15. Hill JJ, Hashimoto T, Lewis DA. Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia. *Mol Psychiatry*. 2006;11:557–566.
16. Cahill ME, Xie Z, Day M, et al. Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes. *Proc Natl Acad Sci U S A*. 2009;106:13058–13063.
17. Hayashi-Takagi A, Takaki M, Graziane N, et al. Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. *Nat Neurosci*. 2010;13:327–332.

18. Penzes P, Jones KA. Dendritic spine dynamics—a key role for kalirin-7. *Trends Neurosci.* 2008;31:419–427.
19. Kothiyal P, Cox S, Ebert J, et al. An overview of custom array sequencing. *Curr Protoc Hum Genet.* 2009;61:7.17.1–7.17.11.
20. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. *Nat Rev Genet.* 2010;11:415–425.
21. Ikeda M, Aleksic B, Kirov G, et al. Copy number variation in schizophrenia in the Japanese population. *Biol Psychiatry.* 2010;67:283–286.
22. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. *Nat Methods.* 2010;7:248–249.
23. Ferrer-Costa C, Gelpi JL, Zamakola L, et al. PMUT: a web-based tool for the annotation of pathological mutations on proteins. *Bioinformatics.* 2005;21:3176–3178.
24. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. *Nat Genet.* 2006;38:209–213.
25. Vassos E, Collier DA, Holden S, et al. Penetrance for copy number variants associated with schizophrenia. *Hum Mol Genet.* 2010;19:3477–3481.
26. O'Donovan MC, Craddock N, Norton N, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. *Nat Genet.* 2008;40:1053–1055.
27. Johnson RC, Penzes P, Eipper BA, Mains RE. Isoforms of kalirin, a neuronal Dbl family member, generated through use of different 5'- and 3'-ends along with an internal translational initiation site. *J Biol Chem.* 2000;275:19324–19333.
28. Keshava Prasad TS, Goel R, Kandasamy K, et al. Human Protein Reference Database—2009 update. *Nucleic Acids Res.* 2009;37:D767–D772.
29. Amanchy R, Periaswamy B, Mathivanan S, et al. A curated compendium of phosphorylation motifs. *Nat Biotechnol.* 2007;25:285–286.
30. Thomson M, Gunawardena J. Unlimited multistability in multisite phosphorylation systems. *Nature.* 2009;460:274–277.
31. Wang L, Hauser ER, Shah SH, et al. Peakwide mapping on chromosome 3q13 identifies the kalirin gene as a novel candidate gene for coronary artery disease. *Am J Hum Genet.* 2007;80:650–663.
32. Krug T, Manso H, Gouveia L, et al. Kalirin: a novel genetic risk factor for ischemic stroke. *Hum Genet.* 2010;127:513–523.
33. Henkemeyer M, Itkis OS, Ngo M, Hickmott PW, Ethell IM. Multiple EphB receptor tyrosine kinases shape dendritic spines in the hippocampus. *J Cell Biol.* 2003;163:1313–1326.
34. Steinberg S, Mors O, Borglum AD, et al. Expanding the range of ZNF804A variants conferring risk of psychosis [published online ahead of print January 05, 2010]. *Mol Psychiatry.* doi: 10.1038/mp.2009.149.
35. Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet.* 2010;42:579–589.
36. Johansen CT, Wang J, Lanktree MB, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. *Nat Genet.* 2010;42:684–687.
37. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. *Nat Genet.* 2008;40:695–701.
38. Yamaguchi-Kabata Y, Nakazono K, Takahashi A, et al. Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. *Am J Hum Genet.* 2008;83:445–456.



Effects of aging on the morphologies of Heschl's gyrus and the superior temporal gyrus in schizophrenia: A postmortem study

Youta Torii ^{a,*}, Shuji Iritani ^{a,b,c}, Hirotaka Sekiguchi ^a, Chikako Habuchi ^a, Minako Hagikura ^a, Tetsuaki Arai ^d, Kenji Ikeda ^e, Haruhiko Akiyama ^c, Norio Ozaki ^a

^a Department of Psychiatry, Graduate School of Medicine, Nagoya University, 65 Tsurumai, Showa-ku, Nagoya, Aichi 466-8550, Japan

^b Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, 2-1-1 Kamikitazawa, Setagaya-ku, Tokyo 156-0057, Japan

^c Department of Psychogeriatrics, Tokyo Institute of Psychiatry, Tokyo Metropolitan Organization for Medical Research, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo 156-8585, Japan

^d Department of Psychiatry, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tenno-dai, Tsukuba, Ibaraki 305-8575, Japan

^e Inflammation Pathology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan

ARTICLE INFO

Article history:

Received 16 May 2011

Received in revised form 9 October 2011

Accepted 29 October 2011

Available online 23 November 2011

Keywords:

Schizophrenia

Postmortem study

Aging

Heschl's gyrus

Superior temporal gyrus

Neuropathology

ABSTRACT

The etiology of schizophrenia has been proposed to be neurodevelopmental based on neuroimaging and molecular biological studies. If there is neuronal vulnerability based on neurodevelopment failures in schizophrenic brains, then the impact of aging may have a greater effect on schizophrenic brains than on normal brains. To determine the impact of aging on schizophrenic brains, we investigated the age-related morphological changes of the cross-sectional area of the gray matter (GM) in the left Heschl's gyrus (HG) and the left superior gyrus (STG) in 22 schizophrenic and 24 age- and sex-matched normal control postmortem brains two-dimensionally. The subject groups were divided into younger groups (30–54 years of age) and older groups (65–84 years of age) on the basis of age at death. Both in schizophrenic and control subjects, the GM area in HG and the STG was significantly smaller in the older group than in the younger group, however, no significant differences were observed between the schizophrenic and control subjects. In the STG, the cross-sectional area of the white matter (WM) was also measured. In the older group, the ratio of the GM area to the WM area in the STG was significantly larger in schizophrenic subjects than controls, although there was no significant difference between the schizophrenic and control subjects in the younger group. These findings indicate that the impact of aging has a greater effect on the WM in the STG in schizophrenic subjects than in normal individuals, although the pathological basis is still unclear.

© 2011 Elsevier B.V. All rights reserved.

1. Introduction

A decreased cortical volume in schizophrenic brains has been repeatedly reported in cross-sectional imaging studies (Honea et al., 2005; Steen et al., 2006) and postmortem studies (Harrison, 1999; Iritani, 2007). It is understood that this morphological change occurs during the very early period of the formation of the central nervous system, because no gliosis has been found in the postmortem brains of schizophrenic patients (Arnold and Trojanowski, 1996). On the other hand, recent longitudinal imaging studies have also reproducibly reported a greater progressive loss of the cortical volume after

disease onset (DeLisi et al., 1997; Kasai et al., 2003b; Nakamura et al., 2007). It is assumed that these phenomena depend on not only neuronal development (Thompson et al., 2001; Vidal et al., 2006) but also continued neuronal degeneration, the long-term use of antipsychotic drugs (Lieberman et al., 2005; Thompson et al., 2009) and unknown interactions between aging and schizophrenia (Harrison, 1999). However, the basis of the volumetric change after disease onset still remains unclear.

To investigate the impact of aging on schizophrenia, it is necessary to consider physiological atrophy and the concomitant presence of neurodegenerative disorders (e.g. Alzheimer-type dementia [ATD], frontotemporal lobar degeneration, etc.) separately. Most neuropathological studies have reported the frequency of Alzheimer-type neuropathological changes in schizophrenic brains to be equal to that in the general population (Powchik et al., 1998; Purohit et al., 1998; Jellinger and Gabriel, 1999), but it remains unclear how the physiological changes in the brain volume of schizophrenic patients occurs, compared to that of the normal brain. To investigate the impact of physiological atrophy, it is necessary to select elderly cases without significant neuropathological changes as study subjects. It is

Abbreviations: ATD, Alzheimer-type dementia; BA, Brodmann area; CPZ, chlorpromazine; CSI, circular sulcus of insula; DTI, diffusion tensor imaging; FTS, first transverse sulcus; GAF, Global Assessment of Functioning; GM, gray matter; HG, Heschl's gyrus; HS, Heschl's sulcus; PMI, postmortem interval; SI, sulcus intermedius; STG, superior temporal gyrus; STS, superior temporal sulcus; WM, white matter.

* Corresponding author. Tel.: +81 52 744 2282; fax: +81 52 744 2293.

E-mail address: youtat@med.nagoya-u.ac.jp (Y. Torii).